Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib

Thyroid. 2016 Sep;26(9):1336-7. doi: 10.1089/thy.2016.0159. Epub 2016 Jul 11.

Authors

Fabiana Pani¹, Francesco Atzori², Germana Baghino¹, Francesco Boi¹, Maria Teresa Ionta², Luciana Tanca³, Mario Scartozzi², Stefano Mariotti¹

Affiliations

¹ 1 Endocrinology Unit, Department of Medical Sciences "M. Aresu," University of Cagliari , Cagliari, Italy .
² 2 Medical Oncology Unit, Department of Medical Sciences "M. Aresu," University of Cagliari , Cagliari, Italy .
³ 3 Medical Oncology, Businco Hospital , Cagliari, Italy .

PMID: 27267354
DOI: 10.1089/thy.2016.0159

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Biomarkers
Female
Humans
Hypothyroidism / etiology*
Immunoenzyme Techniques
Indoles / therapeutic use*
Male
Middle Aged
Neoplasm Metastasis
Prognosis
Pyrroles / therapeutic use*
Sunitinib
Survivors
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / pathology*
Thyroiditis, Autoimmune / etiology*
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers
Indoles
Pyrroles
Sunitinib